Ampio: Jumps after starting trial testing lead drug against COVID-19

Ampio Pharmaceuticals

23/07/2020 19:32

** Drug developer's shares  AMPE.A  rise ~10% to 86 cents
    ** Co begins patient enrollment in an early-stage study
testing its experimental treatment, Ampion, for patients
infected with the coronavirus who require supplemental oxygen
 urn:newsml:reuters.com:*:nPn3KcRt2a
    ** Ampion, co's lead drug, is also being tested in
late-stage studies as treatment for pain due to osteoarthritis
 urn:newsml:reuters.com:*:nL4N2DW2S1
    ** Up to Wednesday's close, AMPE shares had risen ~36% this
year

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91  80 6749 1692))